MetaVia
MetaVia is a clinical-stage biotechnology company developing DA-1726 (a dual GLP-1/glucagon agonist for obesity) and vanoglipel (a GPR119 agonist for MASH), operating pre-revenue with exclusive licensing from strategic partner Dong-A ST and trading on NASDAQ under ticker MTVA.
- Company typePublic
- Founded2014
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MetaVia does
MetaVia is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for cardiometabolic diseases, specifically obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's pipeline centers on two core assets: DA-1726, a long-acting dual GLP-1/glucagon receptor agonist oxyntomodulin peptide analog designed as a once-weekly injection for obesity, which demonstrated 9.1% mean body weight reduction at 48mg by Day 54 in a Phase 1 trial; and vanoglipel (DA-1241), an oral GPR119 agonist that has shown 10.2% liver fibrosis reduction versus 10.1% increase for placebo in a Phase 2a MASH trial. Both programs are built on exclusive licensing arrangements with Dong-A ST Co., Ltd., MetaVia's largest investor and strategic partner, which provides R&D, scientific, and CMC manufacturing support. The company also maintains legacy assets (NB-01, NB-02, ANA001, Gemcabene) that are being evaluated for out-licensing, and has an AI-based drug discovery collaboration with Syntekabio using the DeepMatcher platform for indication prioritization.
MetaVia operates a pre-revenue business model with no current product sales or disclosed pricing. Its revenue mechanics are entirely prospective, anticipated to flow from future commercialization of DA-1726 and vanoglipel through traditional pharmaceutical distribution channels, potential licensing deals, or co-promotion partnerships upon FDA approval. The company currently monetizes only via public equity offerings — completing $10 million in 2025 and $9.3 million in 2026 — to fund ongoing clinical development, and reported a $3.8 million net loss in Q1 2026 with cash runway extending only into Q4 2026. Formerly known as NeuroBo Pharmaceuticals Inc., MetaVia executed a strategic rebrand, a 1-for-11 reverse stock split, and refocused the business around cardiometabolic disease. The company trades on NASDAQ under ticker MTVA (previously NRBO under the NeuroBo identity) with a market capitalization of approximately $19.17 million as of January 2026, reflecting its early-stage status and small public float.
The company's go-to-market upon approval will leverage enterprise pharmaceutical partnerships rather than direct sales, given its 11-50 employee headcount and reliance on Dong-A ST for CMC and development infrastructure. Customer segments are defined by therapeutic indication rather than commercial buyer: obesity patients requiring interventional weight management, MASH patients with progressive fatty liver disease, and secondarily type 2 diabetes and dyslipidemia patients. AI capability is limited to a single third-party partnership for target validation rather than embedded in core R&D operations. Overall, MetaVia represents a small-cap, capital-constrained clinical biotech whose strategic value depends on successful advancement of two early-stage drug candidates and eventual partnership or licensing outcomes.
MetaVia firmographics
Firmographics- Name
- MetaVia
- Legal name
- MetaVia Inc.
- Website
- https://metaviatx.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MetaVia is a clinical-stage biotechnology company developing DA-1726 (a dual GLP-1/glucagon agonist for obesity) and vanoglipel (a GPR119 agonist for MASH), operating pre-revenue with exclusive licensing from strategic partner Dong-A ST and trading on NASDAQ under ticker MTVA.
- Ownership category
- akta.pro rank
MetaVia industry classification
Industry- Product category
- Cardiometabolic Therapeutics
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Hepatology & Liver Disease (HLAKAEAB)
Keywords
Where MetaVia is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MetaVia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Anticipated future revenue from commercialization of drug candidates DA-1726 for obesity and vanoglipel for MASH upon regulatory approval. May pursue licensing deals or co-promotion partnerships.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
MetaVia product offering
Product offeringCore offering
MetaVia is a clinical-stage biotechnology company developing multimodal disease-modifying therapies for cardiometabolic diseases. Its lead clinical assets are DA-1726, a once-weekly injectable dual GLP-1/glucagon receptor agonist (oxyntomodulin peptide analog) for obesity, and Vanoglipel (DA-1241), an oral GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also retains legacy assets (NB-01, NB-02, ANA001, Gemcabene) being evaluated for strategic out-licensing.
Product overview
MetaVia is a clinical-stage biotechnology company developing two primary drug candidates for cardiometabolic diseases: DA-1726, a GLP1R/GCGR dual agonist (once-weekly injection for obesity), and vanoglipel (DA-1241), a GPR119 agonist (oral treatment for MASH). The company also maintains legacy assets including NB-01 (diabetic neuropathy), NB-02 (Alzheimer's disease), ANA001 (COVID-19 antiviral), and Gemcabene (dyslipidemia), which are being assessed for strategic out-licensing opportunities.
Differentiator
Problem solved
Functional benefit
Products and services
- DA-1726
Quantifiable outcome
- 9.1% mean body weight reduction at 48 mg dose by Day 54 in obese but otherwise healthy adults
- +4 more outcomes
Companies that use MetaVia
Customer profileSegments3 records
Ideal customer profiles2 records
MetaVia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MetaVia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- Dong-A ST Research CentercorePreclinical combination therapy studies for vanoglipel conducted in partnership with Dong-A ST Research Center, demonstrating synergistic hepatoprotective and weight-loss effects when combined with resmetirom (MASH model) and enhanced glycemic control when combined with metformin (T2D model).
- Dong-A ST Co., Ltd.coreMetaVia has a strategic partnership and licensing agreement with Dong-A ST Co., Ltd., part of the Dong-A Socio Group established in 1932 and based in South Korea. Dong-A ST is MetaVia's largest investor and provides full support including access to R&D, scientific, and CMC (manufacturing) expertise. The licensing agreement covers DA-1726 and related compounds with exclusive rights for global development and commercialization.
- SyntekabiosupportingAI-based drug discovery collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for vanoglipel (DA-1241). The partnership identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas for GPR119 agonism. The company plans to continue using Syntekabio's AI platform to explore additional indications and optimize the drug's therapeutic profile.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
MetaVia competitors and assessment
Company assessmentDirect peers
- Inventiva: Clinical-stage French biotech developing lanifibranor for MASH. Directly comparable pre-commercial MASH player; both are pursuing oral therapies for the same cardiometabolic liver indication.
- Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH with strong Phase 2b fibrosis data. Competes with MetaVia's vanoglipel in the MASH space and is similarly sized pre-commercial.
- Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601 (oral GLP-1 agonist for obesity) and MASH assets. Comparable as a small-cap dual-indication cardiometabolic company pursuing oral obesity therapy.
- 89bio: Clinical-stage biotech developing pegozafermin for MASH. Directly comparable as a small-cap MASH-focused company with similar Phase 2/3-stage assets competing for the same patient population.
- Structure Therapeutics: Clinical-stage biotech developing oral GLP-1 agonists (GSBR-1290) for obesity and related cardiometabolic conditions. Comparable mechanism (oral incretin) and target indication to MetaVia's DA-1726 program.
- Madrigal Pharmaceuticals: Developer of Rezdiffra (resmetirom), the first FDA-approved MASH therapy. Directly comparable as a MASH-focused biotech; MetaVia's vanoglipel + resmetirom combination work targets the same indication.
- Viking Therapeutics: Clinical-stage biotech developing VK2735 (oral/dual GLP-1/GIP agonist for obesity) and VK2809 (MASH). Directly comparable to MetaVia as a small-cap dual-indication cardiometabolic biotech with similar market cap and pipeline focus.
Broad incumbents
- Eli Lilly: Developer of tirzepatide (Zepbound/Mounjaro) and the next-generation retatrutide and oral orforglipron. The dominant commercial benchmark for DA-1726's preclinical superiority claims; defines the obesity competitive landscape MetaVia must navigate.
- Novo Nordisk: Developer of semaglutide (Wegovy/Ozempic), the current GLP-1 standard of care that DA-1726 is being benchmarked against in preclinical models. Represents the entrenched obesity market leader MetaVia aims to differentiate from.
Emerging players
- Zealand Pharma: Clinical-stage biotech developing survodutide (dual GLP-1/glucagon agonist) in partnership with Boehringer Ingelheim for obesity and MASH. Highly comparable mechanism (dual GLP-1/glucagon) and indication overlap with MetaVia's DA-1726.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
MetaVia social profiles
Digital presenceMetaVia financial estimates
Financial estimateRevenue estimate
Valuation estimate
MetaVia leadership team
Management profileNumber of profiles
Profiles17 records
MetaVia funding detail
Funding detailFunding overview
Funding rounds9 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MetaVia M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MetaVia
What does MetaVia do?
MetaVia is a clinical-stage biotechnology company developing multimodal disease-modifying therapies for cardiometabolic diseases. Its lead clinical assets are DA-1726, a once-weekly injectable dual GLP-1/glucagon receptor agonist (oxyntomodulin peptide analog) for obesity, and Vanoglipel (DA-1241), an oral GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also retains legacy assets (NB-01, NB-02, ANA001, Gemcabene) being evaluated for strategic out-licensing.
Is MetaVia a public or private company?
MetaVia is a public company. It is classified as public and is currently operating.
When was MetaVia founded?
MetaVia was founded in 2014. It employs 1 to 10 people.
Where is MetaVia based?
MetaVia is headquartered in Boston, United States, in the North America region.
How does MetaVia make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are MetaVia's main competitors?
Direct peers on record are Inventiva, Akero Therapeutics, Terns Pharmaceuticals, 89bio, Structure Therapeutics, Madrigal Pharmaceuticals and Viking Therapeutics. Broad incumbents are Eli Lilly and Novo Nordisk. Zealand Pharma is listed as an emerging player.
Does MetaVia have an API?
No public API is recorded for MetaVia.
What industry is MetaVia in?
MetaVia's product category is Cardiometabolic Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals.